Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See.
作者信息
Pischel Lauren, Goshua George
机构信息
Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
出版信息
Clin Infect Dis. 2021 Dec 6;73(11):2119-2120. doi: 10.1093/cid/ciab459.
Abstract
摘要
相似文献
1
Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See.托珠单抗治疗重症2019冠状病毒病的成本效益：看或不看
Clin Infect Dis. 2021 Dec 6;73(11):2119-2120. doi: 10.1093/cid/ciab459.
2
Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality.托珠单抗联合地塞米松的成本效益治疗可降低 COVID-19 死亡率。
Clin Infect Dis. 2021 Dec 6;73(11):2116-2118. doi: 10.1093/cid/ciab409.
3
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
4
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
5
Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.接受托珠单抗治疗的2019冠状病毒病（COVID-19）患者的结局异质性
Clin Infect Dis. 2022 Apr 28;74(8):1504. doi: 10.1093/cid/ciab816.
6
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
7
Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies.托珠单抗与 COVID-19：2120 例重症患者的荟萃分析及其对临床试验方法学的影响。
Turk J Med Sci. 2021 Jun 28;51(3):890-897. doi: 10.3906/sag-2010-131.
8
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?托珠单抗降低重症 COVID-19 患者死亡率：我们应如何对其进行分级？
Br J Clin Pharmacol. 2022 Jul;88(7):3539-3541. doi: 10.1111/bcp.15283. Epub 2022 Mar 2.
9
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19.严重 COVID-19 的调整剂量地塞米松和托珠单抗联合治疗。
Yonsei Med J. 2022 May;63(5):430-439. doi: 10.3349/ymj.2022.63.5.430.
10
Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.托珠单抗治疗 COVID-19：Cerrahpaşa-PREDICT 评分。
J Infect Chemother. 2021 Sep;27(9):1329-1335. doi: 10.1016/j.jiac.2021.05.007. Epub 2021 May 12.
Zotero 插件